Seguridad en anestesia: error en la administración de fármacos LASA / Safety in anesthesia: an error in the administration of LASA drugs / Segurança na anestesia: um erro na administração de drogas LASA

La seguridad del paciente es prioritaria en el ámbito anestésico quirúrgico. El error en la administración de fármacos es una causa frecuente de incidentes críticos en el perioperatorio. Una forma de error, es la administración del medicamento equivocado debido a las presentaciones similares. El objetivo de este trabajo es la descripción de fallas en las barreras de prevención de incidentes críticos con medicamentos, en base al estudio de un caso clínico y al análisis de sus consecuencias. Metodología : Descripción de un caso clínico y estudio sistemático de la situación de riesgo en base al análisis taxonómico del paciente, individuo, tarea, equipo humano, lugar de trabajo y organización (PITELO) sugerido por el Sistema Español de Notificación en Seguridad en Anestesia y Reanimación (SENSAR). Resultados : Mujer sana que presentó paro respiratorio luego de la administración intravenosa de un fármaco en el postoperatorio. Se requirió 24 hs de terapia intensiva y múltiples estudios, luego de lo cual se diagnosticó un error en la administración de fármaco. La confusión se presentó con una dupla de ampollas LASA (del inglés: look-alike, sound-alike) de los fármacos atracurio y ranitidina. La documentación fotográfica evidencia la similitud y el diagrama identifica fallas latentes del sistema. Se estimaron los costos del error y se realizaron propuestas de mejora. Discusión y conclusiones : Se evidencia una falla en las barreras de prevención de eventos adversos y en el sistema de reporte de los mismos. Es necesario incrementar la cultura de seguridad en todos los niveles del sistema: regulatorio, institucional y personal.

Patient safety is a priority in the surgical anesthetic area, and errors in drug administration area frequent cause of critical incidents in the perioperative period. One type of error is the administration of the wrong medication due to similar presentations. The objective of this study is to describe the failure of barriers to prevent critical drug incidents; this is based on the study of a clinical case and an analysis of its consequences. Methodology . Description of a clinical case and systematic study of the risk situation based on the taxonomic analysis of the patient, individual, task, human team, workplace, and organization (PITELO), as suggested by the Spanish System of Safety Notification in Anesthesia and Resuscitation (SENSAR). Results . A healthy woman presented in respiratory arrest after the intravenous administration of a drug in the postoperative period. It took 24 hours of intensive care and multiple studies before an error in drug administration was diagnosed. The confusion was presented with a pair of LASA (look-alike, sound-alike) ampoules of atracurium and ranitidine drugs. Photographic documentation evidences the similarity of the ampoules themselves, and the diagram identifies latent system failures. The costs of the error are estimated and proposals for improvement are provided. Discussion and Conclusions . There is evidence of a failure in the barriers to the prevention of adverse events and in the reporting system. It is necessary to increase the safety culture at all levels of the system: regulatory, institutional, and personal.

A segurança do paciente é prioritária no âmbito anestésico cirúrgico. O erro na administração de fármacos é uma causa frequente de incidentes críticos no perioperatório. Uma forma de erro é a administração de medicação errada devido a uma apresentação similar. O objetivo deste trabalho é a descrição de falhas nas barreiras de prevenção de incidentes críticos com medicamentos, em base no estudo de um caso clínico e ao análise de suas consequências. Metodologia . Descrição de um caso clínico e estudo sistemático da situação de risco em base ao análises taxonômico do doente, tarefa, equipamento humano, lugar de trabalho e organização (PITELO) sugerido pelo Sistema Espanhol de Notificação em Segurança em Anestesia e Reanimação (SENSAR). Resultados . Mulher sem patologia que apresentou paro respiratório a pois a administração intravenosa de um fármacos no pós-operatório. Requereu-se de 24 hs na UTI e múltiplos estudos, logo dos quais foi diagnosticado um erro na administração do fármaco. A confusão se apresentou como causa deduplas ampolas LASA (do inglês: aparência parecida com o som) dos fármacos atracurio y ranitidina. A documentação fotográfica evidencia a similitude e o diagrama identificafalhas latentes no sistema. Foram analisados os custos do erro e realizou-se propostas de melhora. Discussão y conclusões . Evidencia-se uma falla nas barreiras de prevenção de eventos adversos e no sistema de reporte dos mesmos. É necessário incrementar a cultura de segurança em todos os níveis do sistema: regulatório, institucional e pessoal.

Beware of 'lookalikes'.

In 2014, health staff who were vaccinating children in rebel-held northern Syria accidentally administered a muscle relaxant, atracurium, to up to 75 children, killing 15 of them. An investigation found that the drug was given to the children instead of a solution used to mix measles vaccines because the packaging was similar.

Suicide with cisatracurium and thiopental: forensic and analytical aspects.

The suicide of a 43-year-old male by intravenous injection of cisatracurium, a non-depolarizing neuromuscular blocking agent, and thiopental, an ultra-short-acting barbiturate, is presented. Systematic toxicological screening by gas chromatography-mass spectrometry (GC-MS), liquid chromatography (LC)-diode-array detection, and LC-MS-MS confirmed the presence of thiopental. A large peak in the GC-MS chromatogram was matched by the Pfleger-Maurer library as corlumine, but neither atracurium neither its metabolite, laudanosine, were detected. To confirm the absence or the presence of laudanosine in the blood sample, an ultra-performance liquid chromatography-MS-MS method for cisatracurium and laudanosine quantification was developed. The calibration range was 2.5-500 ng/mL for laudanosine and 10-500 ng/mL for cisatracurium. The biases were lower than 12.3%. Intraday and interday precisions, expressed as coefficient of variation, were lower than 13.3%. This method allowed to confirm the presence of laudanosine and measurement of laudanosine in all samples. The femoral blood concentration was therapeutic (0.46 µg/mL). This case report documents a possible analytical pitfall and describes a simple and fast method for cisatracurium determination. Moreover, the purpose of this case report was to document the postmortem redistribution of cisatracurium and laudanosine, which could help make it possible to interpret tissue or cardiac blood concentrations in forensic cases where femoral blood is not available.

Anesthesiologist suicide with atracurium.

Atracurium is a nondepolarizing skeletal muscle relaxant used to facilitate endotracheal intubation and to induce skeletal muscle relaxation during surgery or mechanical ventilation. The drug undergoes a spontaneous non-enzymatic biotransformation, yielding laudanosine and an acrylate moiety. This report documents the case of a 45-year-old anesthesiologist who was found dead at the hospital where he worked. The victim was known to be depressed and undergoing treatment with venlafaxine. An empty syringe was found near the body. Toxicological analysis revealed the presence of laudanosine in the syringe, 0.6 mg/L of laudanosine in heart blood, 0.3 mg/L in urine, and 0.02 mg/L in vitreous humor. Meanwhile, concentrations of venlafaxine and O-desmethyl-venlafaxine, its active metabolite, were 0.7 and 1.1 mg/L in heart blood, 1.7 and 5.2 mg/L in urine, 0.5 and 0.7 mg/L in vitreous humor, and 400 and 20 mg in gastric content, respectively. All drugs and metabolites involved in the case were detected using gas chromatography with nitrogen-phosphorus detection (GC-NPD) and confirmed using GC-mass spectrometry in full scan mode after solid-phase extraction using Bond-Elut Certify columns. Additional high-performance liquid chromatography coupled to diode-array detection screening also obtained the same results. Quantitation of laudanosine and venlafaxine together with its metabolite was carried out using GC-NPD. No other drugs, including ethanol, were detected. Recoveries for laudanosine and venlafaxine were 89% and 86%, respectively, at 0.5 mg/L; intraday and interday precisions were 2% and 6%, and 3% and 7%, respectively; and limits of detection and quantitation were 6 and 20 ng/mL and 18 and 59 ng/mL, respectively. The linearity of the blood calibration curves was excellent for both drugs with r(2) values of > 0.999 (range 0.1-2.0 mg/L). Based on the autopsy findings, case history, and toxicology results, the forensic pathologists ruled that the cause of death was an overdose of atracurium, and the manner of death was suicide.

Clinical manifestations and neurodevelopmental outcome following an event of accidental intramuscular injection of atracurium in newborns.

UNLABELLED: Pediatric populations are at risk for medication errors that may be associated with mortality and disability. The purpose of this study was to describe the clinical manifestations of seven newborns following an event of accidental intramuscular injection of atracurium and to assess the impact on neurodevelopmental outcome. This study enrolled seven newborns who were accidentally administered 10 mg of atracurium, equivalent to 2.6-3.3 mg/kg, in a local perinatal clinic. Accident reports and hospital records were reviewed to obtain the history and medical data for the event. The survivors were prospectively examined for their growth, health and neurodevelopment until 24 months of age. All newborns showed immediate apnea and cyanosis requiring resuscitation after atracurium injection and presented with respiratory failure and flaccid paralysis on arrival for emergency medical services. One newborn was asystolic despite resuscitation and died of multiple organ failure. Of the five survivors available for follow-up, all achieved favorable growth outcomes. However, four showed mild to significant delay in development; and two manifested mild hypomyelination of cerebral white matter on the brain magnetic resonance imaging. CONCLUSION: Newborns accidentally injected with high doses of atracurium are at risk of death and neurodevelopmental delay. The serious clinical manifestations, developmental delay and cerebral hypomyelination were most likely due to insufficient immediate respiratory assistance following atracurium injection.

The distribution of laudanosine in tissues after death from atracurium injection.

A case is presented involving an acute fatality resulting from self-administration of atracurium, a muscle relaxant by a 45-year-old nurse. In the body, atracurium undergoes a spontaneous non-enzymatic degradation to laudanosine and an acrylate moiety. Laudanosine was quantified using gas chromatography coupled to mass spectrometry after extraction with chloroform-isopropanol-n-heptane (50:17:33 v/v) at pH 9.5 and separation on a HP5-MS capillary column. Laudanosine was subject to postmortem redistribution due to release from drug-rich tissues such as the lung and heart. The heart blood (917 ng/ml) to peripheral blood (390 ng/ml) ratio was 2.4. No other drugs, including ethanol were detected.

Atracurium overdose in a small infant.

An error in setting a syringe driver caused a 2.75 kg infant to receive 37 mg atracurium over 75 minutes. Clinically full recovery of muscle power had returned spontaneously 135 minutes after the infusion was stopped. The child suffered no ill effects. Assay of blood and urine for atracurium and laudanosine confirmed rapid clearance of the drug.